Ambalal Sarabhai Enterprises Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Ambalal Sarabhai Enterprises's earnings have been declining at an average annual rate of -7.4%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 4.8% per year. Ambalal Sarabhai Enterprises's return on equity is 7.9%, and it has net margins of 6.1%.
Belangrijke informatie
-7.4%
Groei van de winst
-7.4%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 17.5% |
| Inkomstengroei | 4.8% |
| Rendement op eigen vermogen | 7.9% |
| Nettomarge | 6.1% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Ambalal Sarabhai Enterprises geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1,789 | 109 | 287 | 0 |
| 31 Mar 24 | 1,743 | 57 | 279 | 0 |
| 31 Dec 23 | 1,655 | 29 | 288 | 0 |
| 30 Sep 23 | 1,577 | 47 | 273 | 0 |
| 30 Jun 23 | 1,627 | 46 | 260 | 0 |
| 31 Mar 23 | 1,710 | 114 | 260 | 0 |
| 31 Dec 22 | 1,810 | 132 | 256 | 0 |
| 30 Sep 22 | 1,888 | 137 | 261 | 0 |
| 30 Jun 22 | 1,977 | 222 | 248 | 0 |
| 31 Mar 22 | 1,976 | 472 | 267 | 0 |
| 31 Dec 21 | 1,923 | 552 | 332 | 0 |
| 30 Sep 21 | 1,952 | 537 | 338 | 0 |
| 30 Jun 21 | 1,797 | 550 | 279 | 0 |
| 31 Mar 21 | 1,652 | 294 | 341 | 0 |
| 31 Dec 20 | 1,537 | 267 | 285 | 0 |
| 30 Sep 20 | 1,394 | 251 | 281 | 0 |
| 30 Jun 20 | 1,293 | 144 | 270 | 0 |
| 31 Mar 20 | 1,335 | 141 | 279 | 0 |
| 31 Dec 19 | 1,397 | 23 | 265 | 0 |
| 30 Sep 19 | 1,447 | 45 | 273 | 0 |
| 30 Jun 19 | 1,468 | 46 | 276 | 0 |
| 31 Mar 19 | 1,519 | 42 | 280 | 0 |
| 31 Dec 18 | 1,489 | 71 | 289 | 0 |
| 30 Sep 18 | 1,417 | 72 | 290 | 0 |
| 30 Jun 18 | 1,317 | 44 | 297 | 0 |
| 31 Mar 18 | 1,250 | 13 | 295 | 0 |
| 31 Mar 17 | 1,339 | -182 | 319 | 0 |
| 31 Mar 16 | 1,321 | 481 | 344 | 0 |
| 31 Mar 15 | 1,245 | -67 | 307 | 0 |
| 31 Mar 14 | 1,047 | -202 | 408 | 1 |
Kwaliteitswinsten: 500009 has high quality earnings.
Groeiende winstmarge: 500009's current net profit margins (6.1%) are higher than last year (2.9%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 500009's earnings have declined by 7.4% per year over the past 5 years.
Versnelling van de groei: 500009's earnings growth over the past year (134.5%) exceeds its 5-year average (-7.4% per year).
Winst versus industrie: 500009 earnings growth over the past year (134.5%) exceeded the Pharmaceuticals industry 19.1%.
Rendement op eigen vermogen
Hoge ROE: 500009's Return on Equity (7.9%) is considered low.